Donald and Barbara Zucker School of Medicine, Hofstra/Northwell, Glen Oaks, NY, USA.
Feinstein Institute for Medical Research, Northwell Health, Glen Oaks, NY, USA.
Acta Psychiatr Scand. 2020 Mar;141(3):178-189. doi: 10.1111/acps.13111. Epub 2019 Oct 31.
Clozapine is the only approved strategy for treatment-resistant schizophrenia, although it is highly underutilized. We aim to generate practical and actionable evidence-based recommendations for the use of this drug considering prescription barriers.
Narrative review.
A consistent body of evidence supports the efficacy of clozapine reducing morbidity and mortality in schizophrenia. The main obstacles to its use are the lack of experience by prescribers and perceived treatment burden. Systematic screening of eligibility, utilization of available resources for consultation, developing a professional network with other stakeholders, as well as optimizing how clozapine is presented to patients is discussed. Furthermore, specific evidence-based recommendations for initiation, maintenance, and safety monitoring with clozapine are provided.
Clozapine prescription is one of the areas in psychiatry with the greatest mismatch between efficacy and utilization in clinical practice. Although multiple barriers to the use of clozapine exist, some of these may be overcome by updates of routine clinical practice.
氯氮平是治疗抵抗性精神分裂症的唯一获批策略,但该药的应用严重不足。我们旨在针对处方障碍,生成实用且可操作的循证推荐意见。
叙述性综述。
大量证据一致表明氯氮平可降低精神分裂症的发病率和死亡率。其应用的主要障碍是处方者经验不足和认为治疗负担重。讨论了包括系统筛查资格、利用现有资源咨询、与其他利益相关者建立专业网络以及优化向患者介绍氯氮平的方式等内容。此外,还提供了氯氮平起始、维持和安全性监测的具体循证推荐意见。
氯氮平的处方是精神科中疗效与临床实践应用差距最大的领域之一。尽管氯氮平的应用存在多种障碍,但通过常规临床实践的更新,其中一些障碍可能会得到克服。